Literature DB >> 26416037

A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma.

Y Yin1, Q Mao, S Chen, N Li, X Li, Y Li.   

Abstract

AIM: The aim of this paper was to explore by a quantitative method whether a 74 MBq 131I scanning activity produces a stunning effect in patients with differentiated thyroid carcinoma (DTC).
METHODS: We included 70 patients with DTC who had their first radioiodine treatment for ablation of thyroid remnants and/or metastases. All the patients received 1850~7400 MBq 131I. Before ablation, 34 patients (group A) performed a diagnostic scan (Dscan) 24 hours after the administration of 74 MBq 131I; 36 patients (group B) received 131I therapy without a previous Dscan. A therapeutic scan (Tscan) was performed after the ablation. The fractional concentrations of 131I in remnants or functional metastases were quantified on Dscan and Tscan, and were expressed as Dx and Tx respectively. The level of significance was set at 0.05.
RESULTS: For group A, 67 foci were found both on Dscan and Tscan, the mean Dx and Tx was 26.13±37.98 and 7.46±10.63 (P=0.000), respectively. For group B, 70 foci were found on Tscan, the mean Tx was 15.23±17.23, which was higher than group A significantly (P=0.002).
CONCLUSION: 74 MBq 131I for diagnostic scan can decrease the uptake of 131I by thyroid remnants or metastases, the thyroid stunning exists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26416037

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  3 in total

1.  Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.

Authors:  Christian Happel; Wolfgang Tilman Kranert; Hanns Ackermann; Ina Binse; Benjamin Bockisch; Daniel Gröner; Ken Herrmann; Frank Grünwald
Journal:  Endocrine       Date:  2018-12-31       Impact factor: 3.633

2.  The Molecular Effect of Diagnostic Absorbed Doses from 131I on Papillary Thyroid Cancer Cells In Vitro.

Authors:  Mariusz Stasiołek; Zbigniew Adamczewski; Przemysław W Śliwka; Bartosz Puła; Bolesław Karwowski; Anna Merecz-Sadowska; Marek Dedecjus; Andrzej Lewiński
Journal:  Molecules       Date:  2017-06-15       Impact factor: 4.411

3.  Prognostic Impact of Direct 131I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study.

Authors:  José F Carrillo; Rafael Vázquez-Romo; Margarita C Ramírez-Ortega; Liliana C Carrillo; Edgar Gómez-Argumosa; Luis F Oñate-Ocaña
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-29       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.